The Latest Breaking News from PRGO

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Perrigo plc (NYSE:PRGO), the largest maker of over-the-counter healthcare products, is at the center of a years-long legal dispute stemming from its rejection of a takeover bid and subsequent fallout that cost shareholders billions.

The pharmaceutical industry is booming because of the increasing need for quality healthcare and high-quality medicines, the fast-growing elderly population, and the uptick in chronic illnesses. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Perrigo Company (PRGO), ACADIA Pharmaceuticals (ACAD), and Pacira BioSciences…

The pharmaceutical industry’s prospects look bright, fueled by a rapidly aging population, the rising prevalence of chronic diseases, consistent R&D efforts backed by government funding, and digital transformation. Pharma stocks Relay Therapeutics (RLAY) and Perrigo Company (PRGO) should benefit from the industry tailwinds. But let’s find out which stock holds…

The shares of leading baby formula maker Perrigo Company (PRGO) have been soaring in price of late amid a nationwide baby formula shortage. So, because the crisis is expected to continue through the coming months, will PRGO be able to maintain this momentum in the near term? Read more to…

Perrigo Company plc's (NYSE: PRGO) Q1 FY22 sales increased 6.4% Y/Y to $1.07 billion, almost in line with the consensus of $1.1 billion. The growth was led by strong consumer demand, particularly for cough/cold products globally and infant formula in the U.S. after competitor recall. Adjusted EPS decreased 34% to $0.33, as higher sales…

Perrigo Company plc (NYSE: PRGO) 

  Perrigo (NYSE:PRGO) reported its Q4 earnings results on Tuesday, March 1, 2022 at 06:30 AM. Here's what investors need to know about the announcement.